Wells Fargo & Company Eliem Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 13,248 shares of ELYM stock, worth $54,449. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,248
Previous 3,149
320.7%
Holding current value
$54,449
Previous $22,000
204.55%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding ELYM
# of Institutions
69Shares Held
53.1MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA31.4MShares$129 Million2.23% of portfolio
-
Janus Henderson Group PLC London, X03.61MShares$14.8 Million0.01% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.61MShares$10.7 Million7.7% of portfolio
-
Boxer Capital, LLC San Diego, CA2.6MShares$10.7 Million0.7% of portfolio
-
Deep Track Capital, LP Greenwich, CT2.17MShares$8.92 Million0.41% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...